Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma
Clinical trial NCT05411497 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05411497
- Sponsor
- Mayo Clinic
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-20
- Primary completion
- 2027-08-18
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.